Employees: 485
Size Ginkgo Bioworks (DNA) is a United States Health Care company (Medical/Nursing Services) with a market value of $547M, the 2608th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.44 on 18 Nov 2026.
Performance Over six months the shares gained 9.3%, against -8.3% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue fell 44.2% over the last twelve months (peer median +6.0%); the operating margin is -242.3% (peer median 8.2%).
Valuation It trades at 6.5× enterprise value to sales against a peer median of 1.4× (3rd most expensive of 21).
Capital Return on invested capital runs 48.7 points below its cost of capital (10.3% WACC).
Backlog Backlog (remaining performance obligations) was $126M at 30 Sep 2026, up 54% on a year earlier — 1.0 years of trailing revenue. Backlog detail →
Short interest Short interest is 17.1% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $101M | $170M | $227M | $251M | $478M |
| Revenue growth | — | -25% | -10% | -47% | — |
| Gross profit | $40.7M | $82.9M | $137M | $143M | $212M |
| EBITDA | -$193M | -$255M | -$397M | -$601M | -$2.10B |
| Net income | -$276M | -$313M | -$547M | -$893M | -$2.10B |
| Free cash flow | -$174M | -$179M | -$382M | -$336M | -$304M |
| Capital expenditure | $6.56M | $7.67M | $62.5M | $40.8M | $52.3M |
| Total debt | $397M | $440M | $468M | $242M | $443M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DNA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.4% | -2.6% | 7th lowest of 21 |
| 6-month return | +9.3% | -8.3% | 4th highest of 20 |
| Distance from 52-week high | -53.7% | -30.8% | 4th lowest of 21 |
| Revenue growth (TTM) | -44.2% | +6.0% | lowest of 21 |
| Operating margin | -242.3% | 8.2% | lowest of 21 |
| EV / Sales | 6.5× | 1.4× | 3rd most expensive of 21 |
| ROIC minus cost of capital | -48.7 pp | -0.3 pp | 2nd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | 6.5× | n/a | n/a |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | 2.3× | 5.9% | +3.2% |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | 25.2× | n/a | n/a |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 1.2× | 10.1% | +94.5% |
| Strata Critical Medical SRTA | United States | $443M | -10% | +23% | -4% | 1.4× | n/a | n/a |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | 1.2× | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 5.6× | 36.6% | +31.6% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 0.9× | -19.6% | -4.0% |
| Australian Clinical Labs ACL.AX | Australia | $418M | +68% | -1% | 8% | 1.3× | 4.3% | +2.6% |
| Integral Diagnostics IDX.AX | Australia | $413M | -22% | +26% | 9% | 1.5× | 7.8% | +17.7% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 2.8× | 17.8% | +12.4% |
| Jeena Sikho Lifecare JSLL.NS | India | $394M | -55% | +135% | 32% | 4.0× | 7.3% | +42.6% |
| ADICON 9860.HK | Hong Kong | $393M | +5% | +1% | 4% | 1.3× | 12.3% | -1.5% |
| HK inno.N 195940.KS | South Korea | $783M | -28% | +7% | 12% | 1.3× | -4.7% | +12.2% |
| M1 Kliniken M12.DE | Germany | $368M | +1% | -28% | 13% | 1.2× | -5.3% | +17.9% |
| Terveystalo Oy TTALO.HE | Finland | $832M | -26% | -8% | 8% | 1.2× | -5.1% | +5.3% |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $352M | +17% | 0% | -2% | 0.4× | -14.9% | +9.6% |
| Thyrocare Technologies THYROCARE.NS | India | $858M | +7% | +22% | 26% | 8.5× | 28.5% | +10.9% |
| Tellgen 300642.SZ | China | $328M | -11% | +5% | 8% | 5.2× | 18.8% | -5.8% |
| Oncology Institute STLN | United States | $326M | n/a | +35% | -3% | 0.6× | 5.4% | +21.8% |
| NIOX NIOX.L | United Kingdom | $325M | +3% | +3% | 22% | 4.9× | 3.4% | +15.3% |
Ginkgo Bioworks reported $126M of remaining performance obligations at 30 Sep 2026, up 54% from a year earlier and up 11% from the previous quarter. That is 1.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.46.